期刊文献+

莫达非尼对人体基础+G_z耐力和科里奥利加速度耐力的影响 被引量:2

Effects of modafinil on human basic +G_z tolerance and Coriolis acceleration tolerance
原文传递
导出
摘要 目的观察服用莫达非尼对人体基础+Gz耐力、科里奥利加速度耐力的影响,为飞行人员合理用药提供有关试验依据。方法7名健康青年男性志愿者为受试者,试验分两批:①受试者于8∶00~9∶00交叉服用莫达非尼和安慰剂200mg(相隔1周)后1h进行基础+Gz耐力测定,并在+Gz暴露前后测定受试者的血压和脉搏;②受试者于8∶00~9∶00交叉服用莫达非尼和安慰剂200mg(相隔1周)后1h进行科里奥利加速度耐力的检测。结果服用莫达非尼与安慰剂后1h,两组的基础+Gz耐力分别为3.86±0.24和3.79±0.27、科里奥利加速度耐力分别为25.57±11.67和30.56±10.25,莫达非尼与安慰剂间的观测指标均无明显差异。结论服用莫达非尼200mg起效后对人体基础+G耐力和抗运动病能力均无明显不良影响。 Objective To observe the effects of modafinil on human basic +Gz tolerance and Coriolis acceleration tolerance. Methods Seven healthy young male volunteers served as subjects. The experiment was divided into two parts: ① subjects administered modafinil (200mg) or placebo at 8 : 00~9 : 00 a.m. alternatively with one week interval, and their basic +Gz tolerance was measured 1 h later. Blood pressure and pulse rate were obtained immediately before and after the G-tolerance test. ② subjects administered modafinil (200 mg)or placebo at 8 : 00~9 : 00 a.m. alternatively with one week interval, and their Coriolis acceleration tolerance was measured 1 h later. Results The G tolerance of modafinil group and control group was 3.86 ± 0.24 and 3.79 ±0.27 respectively; and their Coriolis acceleration tolerance was 25.57 ±11.67 and 30.56 ± 10. 25 separately. The differences between modafinil group and control group were both non-significant. Conclusions No significant adverse effects on human basic + Gz tolerance and antimotion sickness ability were found 1 h after taking modafinil 200 mg.
出处 《中华航空航天医学杂志》 CSCD 2005年第2期95-97,共3页 Chinese Journal of Aerospace Medicine
基金 空军后勤科研计划项目(KH0108011)
关键词 莫达非尼 加速度 科里奥利加速度 身体耐力 Modafinil Accelerations Coriolis acceleration Physical endurance
  • 相关文献

参考文献11

二级参考文献46

  • 1于平 《航空医学》编委会.G耐力检查方法及标准.航空医学[M].北京:人民军医出版社,1992.226-236.
  • 2詹皓,关宏.精神药物在战时调节飞行人员睡眠与抗疲劳中的应用[J].中华航空航天医学杂志,1997,8(1):48-51. 被引量:25
  • 3Angus RG, Heslegrave RJ. The effects of sleep loss and sustained mental work: implications for command & control performance. 1983.AD-A 139324.
  • 4Lyons TJ, French J. Modafinil: the unique properties of a new stimulant. Aviat Space Environ Med, 1991, 62(5):432-435.
  • 5Fuxe K, Rambert FA, Ferraro L, et al. Preclinical studies with modafinil: evidence for vigilance enhancement and neuroprotection. Drugs Today, 1996, 32(1):7-21.
  • 6Ferraro L, Fuxe K, Tanganelli S, et al. Differential enhancement of dialysate serotonin levels in distinct brain regions of the awake rat by modafinil: possible relevance for wakefulness and depression. J Neurosci Res, 2002, 68(1): 107-112.
  • 7Moachon F, Kanmacher I, Clenet M, et al. Pharmacokinetic profile of modafinil. Drugs Today, 1996, 32(1):23-33.
  • 8Pigeau R, Naitoh P, Buguet A, et al. Modafinil,d-amphetamine and placebo during 64 hours of sustained mental work. I. Effects on mood, fatigue, congnitive performance and body temperature. J Sleep Res, 1995, 4(4):212-228.
  • 9Lagarde D, Batejat D. Disrupted sleep-wake rhythm and performance: advantages of modafinil. Mil Psychol, 1995, 7(3), 165-191.
  • 10Caldwell Jr JA, Caldwell JL, Smythe Ⅲ NK, et al. A double-blind, placebo-controlled investigation of the efficacy of modafinil for sustaining the alertness and performance of aviators: a helicopter simulator study. Psychopharmacology, 2000, 150(3):272-282.

共引文献52

同被引文献45

引证文献2

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部